Login
Companies $KYMR
$125.10 -$2.47 (1.94%) Live
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc.

kymeratx.com

What Do They Do?

Develops oral small-molecule medicines that remove disease-causing proteins, primarily for people with immune-inflammatory diseases.

How Do They Make Money?

Collaborators pay Kymera for licenses to its drug technology and for research and development work. License fees may be paid upfront or when an option is exercised; research payments arrive under contract billing schedules, with some earned as the work progresses.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical collaborators buy licenses to Kymera’s drug technology and contract research and development work.

Do Revenues Turn Into Profits?

No. It lost $311.4M in FY2025.

Operating income, FY2025
−891% of revenue
▼ −34% (Loss) vs FY2024 (−$261.6M, −556%)
Net income, FY2025
−794% of revenue
▼ −39% (Loss) vs FY2024 (−$223.9M, −476%)
Free cash flow, FY2025
−598% of revenue
▼ −13% (Loss) vs FY2024 (−$207.3M, −440%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −100%
vs $2.8M in Q3 FY2025
Net income
▼ −61% (Loss)
vs −$82.2M in Q3 FY2025
  • Jun 25, 2026 Kymera completed enrollment in its atopic dermatitis trial ahead of schedule. The company moved its expected data readout to year-end 2026 and expects to start Phase 3 trials by mid-2027, subject to regulator discussions.

Shrinking. Revenue fell 46% in 4 years, from $72.8M in FY2021 to $39.2M in FY2025, about 14% a year.

From oncology to immunology The older report described clinical programs across immune-inflammatory diseases and cancer. The latest report centers its disclosed clinical pipeline on immune-inflammatory diseases.

Who Do They Compete With?

Competes with Arvinas, C4 Therapeutics, Nurix Therapeutics, Foghorn Therapeutics, Gilead Sciences, Johnson & Johnson, Pfizer, and Sanofi

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support